A new subgroup analysis reveals that adolescents with moderate-to-severe plaque psoriasis treated with once-daily icotrokinra ...

A new consensus from the National Psoriasis Foundation outlines a clear benchmark for remission to improve treatment decisions and patient outcomes.

Compared with adalimumab, several biologic medications had superior safety profiles for the treatment of moderate to severe psoriasis.

Icotrokinra was safe and effective for improving skin clearance among patients with at least moderate psoriasis in ...

Discover a study that analysed evidence showing that metabolic disturbances can also exacerbate psoriasis symptoms. Learn ...

Discover a study where results suggest a statistically significant association between dupilumab and psoriasis, although the clinical impact may be limited.

Key findings of subgroup analyses included an observed increased psoriasis risk in patients without atopic comorbidities (HR 1.42, 95% CI 1.06-1.89) and those with pretreatment immunoglobulin E (IgE) ...